Fulcrum Tx (FULC): Debts to Book Capitalization

Fulcrum Therapeutics (FULC) generates revenue by developing treatments for rare muscular and genetic pathologies, relying on grants and partnership payments. The business is currently in the testing phase, meaning high laboratory expenses and a lack of regulatory approvals keep margins at 0.02. Historical price action on the GURU.Markets platform accounts for patent dispute risks and logistical complexities associated with the transport of biomaterials.

This indicator measures the proportion of debt capital relative to equity capital, determining the extent to which a company's financial stability depends on external borrowing and the efficiency of its leverage. For the science-driven Fulcrum Therapeutics (FULC), which retains geneticists through RSUs, the ratio of debt to equity on GURU.Markets demonstrates a balance between early-stage research investments and debt load.